Develops gene editing therapies to treat cardiovascular diseases and transform the lives of patients.
Verve Therapeutics, Inc. is a pioneering genetic medicines company focused on advancing innovative treatments for cardiovascular diseases. The company is actively developing cutting-edge gene editing therapies aimed at revolutionizing patient care.
At the forefront of its pipeline is VERVE-101, the company's lead product candidate. VERVE-101 is designed as a single-course gene editing treatment that achieves permanent silencing of the PCSK9 gene in the liver. This approach holds promise for significantly reducing low-density lipoprotein cholesterol levels and mitigating cardiovascular risks in patients.
In addition to VERVE-101, Verve Therapeutics is advancing its ANGPTL3 program, which aims to permanently turn off the ANGPTL3 gene in the liver. These innovative therapies underscore the company's commitment to leveraging genetic insights to address critical medical needs in cardiovascular health.
Originally founded as Endcadia, Inc. and rebranded in January 2019, Verve Therapeutics is headquartered in Cambridge, Massachusetts. The company collaborates extensively within the biotechnology community, holding collaboration and license agreements with industry leaders such as Beam Therapeutics Inc. and Acuitas Therapeutics, Inc. Furthermore, Verve Therapeutics has secured essential Cas9 technology licenses from The Broad Institute and the President and Fellows of Harvard College, positioning itself at the forefront of gene editing innovation.